Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3976707 | Brachytherapy | 2015 | 6 Pages |
Abstract
Toxicity after HDR monotherapy for prostate cancer is acceptable. Patients with larger prostates, longer intraprostatic urethras, and greater doses to the bladder and urethra may experience worse acute urinary QOL. Older patients may experience greater impairment in sexual function in the short and long terms.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
David R. Raleigh, Albert J. Chang, Bryan Tomlin, J. Adam Cunha, Steve E. Braunstein, Katsuto Shinohara, Alexander R. Gottschalk, Mack III, I-Chow Hsu,